First-ever commercial TIL therapy: How NCI, Iovance, and Moffitt achieved FDA approval

In the Headlines: What if curing diseases was treated like a business?

A 25-year old idea, a concept named “the American Centers for Cures,” proposed by Lou Weisbach, a former CEO of a Fortune 500 company and a political insider, aims to shift the paradigm of research funding.

June 25, 2025

Vol.51 No.24

As Trump decimates NIH funding, a daring proposal to issue $750 billion in bonds for medical cures garners attention

As biomedical research at NIH faces an existential threat from the Trump administration, an entrepreneur is winning over allies for what he describes as a “simple idea” that could introduce a massive new infusion of money for innovation in medicine.

June 20, 2025

Vol.51 No.24

By Jacquelyn Cobb

Conversation with The Cancer Letter

Lou Weisbach tells us about his plan to raise $750 billion for the American Center for Cures

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

June 20, 2025

Vol.51 No.24

By Otis W. Brawley and Paul Goldberg

Clinical Trials & Tribulations

Optimizing dosing of expensive and toxic oncology drugs: Making America healthier

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals. But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half. Simply stated, cost is the product of (price per unit times the number of units purchased).

June 20, 2025

Vol.51 No.24

By Mark J. Ratain, David A. Hyman, Jill E. Feldman, Beth R. Jacobson and Allen S. Lichter

Cancer Policy

FDA to issue “national priority vouchers” to companies supporting U.S. interests

A new FDA voucher program will aim to accelerate review time for applications that are deemed to be advancing U.S. “national priorities.”

June 20, 2025

Vol.51 No.24

By Claire Marie Porter

Cancer Policy

Vinay Prasad named chief medical and scientific officer at FDA

Vinay Prasad, a MAHA-aligned hematologist-oncologist with an avid cyber following, who was named director of the FDA Center for Biologics Evaluation and Research in early May (The Cancer Letter, May 9, 2025), has now been also appointed chief medical and science officer at FDA, according to an internal memo obtained by The Cancer Letter.

June 20, 2025

Vol.51 No.24

By Claire Marie Porter

First-ever commercial TIL therapy: How NCI, Iovance, and Moffitt achieved FDA approval

YOU MAY BE INTERESTED IN

In the Headlines: What if curing diseases was treated like a business?

As Trump decimates NIH funding, a daring proposal to issue $750 billion in bonds for medical cures garners attention

Lou Weisbach tells us about his plan to raise $750 billion for the American Center for Cures

Optimizing dosing of expensive and toxic oncology drugs: Making America healthier

FDA to issue “national priority vouchers” to companies supporting U.S. interests

Vinay Prasad named chief medical and scientific officer at FDA

Renew today!

Subscriber content

Never miss an issue!

Login